These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 7749946)

  • 1. In smokers with mild airway disease, quitting slows decline in lung function. Ipratropium offers no lasting benefit.
    Am J Health Syst Pharm; 1995 Feb; 52(3):234. PubMed ID: 7749946
    [No Abstract]   [Full Text] [Related]  

  • 2. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.
    Scanlon PD; Connett JE; Waller LA; Altose MD; Bailey WC; Buist AS; Tashkin DP;
    Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):381-90. PubMed ID: 10673175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
    Anthonisen NR; Connett JE; Kiley JP; Altose MD; Bailey WC; Buist AS; Conway WA; Enright PL; Kanner RE; O'Hara P
    JAMA; 1994 Nov; 272(19):1497-505. PubMed ID: 7966841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early intervention in chronic obstructive pulmonary disease. A review of the Lung Health Study results.
    Kanner RE
    Med Clin North Am; 1996 May; 80(3):523-47. PubMed ID: 8637302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basic medication of chronic obstructive lung disease with berodual].
    Melent'eva EM
    Klin Med (Mosk); 1999; 77(7):47-8. PubMed ID: 10483166
    [No Abstract]   [Full Text] [Related]  

  • 6. [Corticosteroids].
    Löfdahl CG
    Rev Mal Respir; 1998 Sep; 15 Suppl 2():S42-4. PubMed ID: 9809343
    [No Abstract]   [Full Text] [Related]  

  • 7. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group.
    Tashkin DP; Altose MD; Connett JE; Kanner RE; Lee WW; Wise RA
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1802-11. PubMed ID: 8665038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term atrovent treatment of chronic obstructive bronchitis].
    Simanenkov VI; Il'iashevich IG; Liparteliani BG; Ledovaia AV
    Ter Arkh; 1998; 70(9):77-9. PubMed ID: 9821235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lung health study. Disappointment and triumph.
    Gross NJ
    JAMA; 1994 Nov; 272(19):1539-41. PubMed ID: 7966848
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease.
    Dunst MN
    Am Rev Respir Dis; 1989 Oct; 140(4):1174. PubMed ID: 2529802
    [No Abstract]   [Full Text] [Related]  

  • 11. [Bronchial obstruction--therapy with ipratropium bromide. Results of a multicenter clinical study].
    Stauder J; Flasch CI
    Fortschr Med; 1988 Oct; 106(31):631-4. PubMed ID: 2972596
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between long-term treatment of chronic bronchitic airway obstruction with ipratropium bromide and metaproterenol.
    Ashutosh K; Lang H
    Ann Allergy; 1984 Nov; 53(5):401-6. PubMed ID: 6238558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Atrovent (ipratropium bromide) on the mechanics of respiration in patients with chronic obstructive pulmonary disease].
    Malinowski R; Frank-Piskorska A; Wasek Z; Koczorowski T
    Pneumonol Pol; 1986 Mar; 54(3):91-5. PubMed ID: 2942842
    [No Abstract]   [Full Text] [Related]  

  • 14. [Value of ipratropium (Atrovent) in the treatment of chronic obstructive lung diseases in myasthenic patients treated with anticholinesterase agents. Apropos of a case].
    Robinet G; Leroyer C; Andre J; Dewitte JD; Clavier J
    Rev Pneumol Clin; 1989; 45(4):161-3. PubMed ID: 2533994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of muscarinic receptors and calcium channel blockers on bronchial reactivity and ventilation parameters in patients with obstructive lung diseases].
    Siergiejko Z; Kazberuk M; Hofman J; Chyrek-Borowska S
    Pneumonol Alergol Pol; 1991; 59(9-10):28-32. PubMed ID: 1843643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled clinical study of a long-term treatment of chronic obstructive lung disease using a combination of fenoterol and ipratropium bromide in aerosol form.
    Serra C; Giacopelli A
    Respiration; 1986; 50 Suppl 2():249-53. PubMed ID: 2951816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease.
    Braun SR; McKenzie WN; Copeland C; Knight L; Ellersieck M
    Arch Intern Med; 1989 Mar; 149(3):544-7. PubMed ID: 2521997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ipratropium bromide in COPD. Cost effectiveness of the treatment of COPD with ipratropium bromide].
    Puig X
    Aten Primaria; 1995 Mar; 15(4):208. PubMed ID: 7703328
    [No Abstract]   [Full Text] [Related]  

  • 19. [The cholinergic component of airway obstruction].
    Ulmer WT; Schwabl U
    Fortschr Med; 1987 Jan; 105(3):43-7. PubMed ID: 2951304
    [No Abstract]   [Full Text] [Related]  

  • 20. Bronchodilating and density dependence effects of fenoterol, ipratropium bromide and Duovent in reversible chronic obstructive pulmonary disease.
    Dubois PE; Delwiche JP; Minette P; Lulling J; Prignot J
    Respiration; 1986; 50 Suppl 2():280-4. PubMed ID: 2951822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.